First Time Loading...

Concert Pharmaceuticals Inc
NASDAQ:CNCE

Watchlist Manager
Concert Pharmaceuticals Inc Logo
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Watchlist
Price: 8.37 USD Market Closed
Updated: Apr 27, 2024

Concert Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Concert Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Revenue
$32.6m
CAGR 3-Years
46%
CAGR 5-Years
177%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Concert Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Concert Pharmaceuticals Inc

Not Available

Breakdown by Segments
Concert Pharmaceuticals Inc

Total Revenue: 32.6m USD
100%
Other Revenue: 32.5m USD
99.9%
License And Research And Development Revenue: 39k USD
0.1%

See Also

What is Concert Pharmaceuticals Inc's Revenue?
Revenue
32.6m USD

Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Revenue amounts to 32.6m USD.

What is Concert Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
177%

Over the last year, the Revenue growth was 312%. The average annual Revenue growth rates for Concert Pharmaceuticals Inc have been 46% over the past three years , 177% over the past five years .